Marizyme (MRZM) 10-Q 5 Mar 25 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Mar. 05, 2025
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	000-53223
Entity Registrant Name	MARIZYME, INC.
Entity Central Index Key	0001413754
Entity Tax Identification Number	82-5464863
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	555 Heritage Drive
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Jupiter
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33458
City Area Code	(561)
Local Phone Number	935-9955
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		131,793,088
Entity Listing, Par Value Per Share	$ 0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current
Cash	$ 63,732	$ 148,465
Accounts receivable	2,000	60,284
Other receivables	35,879	35,797
Prepaid expenses	726,114	699,377
Inventory	26,869	24,855
Total current assets	854,594	968,778
Non-current
Property, plant and equipment, net		12,500
Operating lease right-of-use assets, net	797,405	1,101,211
Intangible assets, net	14,037,798	14,364,129
Prepaid royalties, non-current	120,500	122,457
Deposits	30,000	30,000
Goodwill	5,416,000	5,416,000
Total non-current assets	20,401,703	21,046,297
Total assets	21,256,297	22,015,075
Current
Accounts payable and accrued expenses	3,371,483	2,322,064
Notes payable	2,739,981	633,692
Convertible notes, net - Units Private Placement	16,698,700	16,328,476
Convertible notes, net - OID	6,421,918	2,694,256
Operating lease obligations	442,221	434,082
Total current liabilities	29,977,203	22,642,723
Non-current
Operating lease obligations, net of current portion	355,184	667,129
Agreement obligation	1,000,000
Contingent liabilities	5,463,000	5,406,000
Total non-current liabilities	6,818,184	6,073,129
Total liabilities	36,795,387	28,715,852
Commitments and contingencies (Note 10)
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding as of September 30, 2024 and December 31, 2023
Common stock, par value $0.001, 2,000,000,000 shares authorized, issued and outstanding shares - 131,793,088 at September 30, 2024 and December 31, 2023	131,792	131,792
Additional paid-in capital	154,650,064	148,696,200
Accumulated deficit	(170,320,946)	(155,528,769)
Total stockholders’ equity (deficit)	(15,539,090)	(6,700,777)
Total liabilities and stockholders’ equity (deficit)	21,256,297	22,015,075
Related Party [Member]
Current
Due to related parties	$ 302,900	$ 230,153

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	131,793,088	131,793,088
Common stock, shares outstanding	131,793,088	131,793,088

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenue		$ 181,535	$ 32,855	$ 495,248
Direct cost of revenue		50,989	9,647	139,875
Gross profit		130,546	23,208	355,373
Operating expenses:
Professional fees (includes related party amounts of $89,500, $72,000, $319,500, and $216,000, respectively)	118,270	921,552	721,042	1,818,202
Salary expenses	318,019	329,564	983,703	931,536
Research and development	344,139	492,235	978,339	1,789,625
Stock-based compensation	20,794	86,132	116,646	457,860
Depreciation and amortization	108,777	210,293	338,831	630,924
Royalty expense		13,014	1,957	211,262
Other general and administrative expenses	445,031	2,934,966	1,199,172	6,310,039
Total operating expenses	1,355,030	4,987,756	4,339,690	12,149,448
Total operating loss	(1,355,030)	(4,857,210)	(4,316,482)	(11,794,075)
Other income (expense)
Interest and accretion expenses	(1,104,674)	(1,502,088)	(6,230,294)	(11,038,400)
Other income			200,000
Change in fair value of contingent liabilities	440,000	(1,678,000)	(57,000)	312,000
Change in fair value of derivative liabilities		(14,454,397)		(14,454,397)
Gain (loss) on debt extinguishment	59,843	(80,000)	(3,888,401)	(21,857,877)
Borrowing costs			(500,000)
Loss on issuance of debt		(3,974,993)		(6,352,562)
Total other income (expense)	(604,831)	(21,689,478)	(10,475,695)	(53,391,236)
Net loss	$ (1,959,861)	$ (26,546,688)	$ (14,792,177)	$ (65,185,311)
Loss per share - basic	$ (0.01)	$ (0.58)	$ (0.11)	$ (1.51)
Loss per share - diluted	$ (0.01)	$ (0.58)	$ (0.11)	$ (1.51)
Weighted average number of shares of common stock outstanding - basic	131,793,088	45,812,412	131,793,088	43,270,975
Weighted average number of shares of common stock outstanding - diluted	131,793,088	45,812,412	131,793,088	43,270,975

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Related Party [Member]
Related Party Transaction [Line Items]
Professional fees related paty	$ 89,500	$ 72,000	$ 319,500	$ 216,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 40,528	$ 103,370,890	$ (85,989,433)	$ 17,421,985
Balance, shares at Dec. 31, 2022	40,528,191
Stock-based compensation expense		210,966		210,966
Issuance of shares	$ 240	153,360		153,600
Issuance of shares, shares	240,000
Net loss			(2,554,584)	(2,554,584)
Balance at Mar. 31, 2023	$ 40,768	103,735,216	(88,544,017)	15,231,967
Balance, shares at Mar. 31, 2023	40,768,191
Balance at Dec. 31, 2022	$ 40,528	103,370,890	(85,989,433)	17,421,985
Balance, shares at Dec. 31, 2022	40,528,191
Net loss				(65,185,311)
Balance at Sep. 30, 2023	$ 46,666	121,726,501	(151,174,744)	(29,401,577)
Balance, shares at Sep. 30, 2023	46,666,760
Balance at Mar. 31, 2023	$ 40,768	103,735,216	(88,544,017)	15,231,967
Balance, shares at Mar. 31, 2023	40,768,191
Stock-based compensation expense		160,762		160,762
Issuance of shares	$ 1,946	339,050		340,996
Issuance of shares, shares	1,946,410
Net loss			(36,084,039)	(36,084,039)
Exercise of warrants	$ 2,652	262,564		265,216
Exercise of warrants, shares	2,652,159
Increase of fair value of warrants in debt extinguishment		12,666,268		12,666,268
Issuance of warrants on promissory note		1,333,128		1,333,128
Balance at Jun. 30, 2023	$ 45,366	118,496,988	(124,628,056)	(6,085,702)
Balance, shares at Jun. 30, 2023	45,366,760
Stock-based compensation expense		86,132		86,132
Issuance of shares	$ 1,300	208,700		210,000
Issuance of shares, shares	1,300,000
Net loss			(26,546,688)	(26,546,688)
Exercise of warrants		2,934,681		2,934,681
Balance at Sep. 30, 2023	$ 46,666	121,726,501	(151,174,744)	(29,401,577)
Balance, shares at Sep. 30, 2023	46,666,760
Balance at Dec. 31, 2023	$ 131,792	148,696,200	(155,528,769)	(6,700,777)
Balance, shares at Dec. 31, 2023	131,793,088
Stock-based compensation expense		54,264		54,264
Net loss			(5,396,490)	(5,396,490)
Increase of fair value of warrants in debt extinguishment		1,407,934		1,407,934
Balance at Mar. 31, 2024	$ 131,792	150,158,398	(160,925,259)	(10,635,069)
Balance, shares at Mar. 31, 2024	131,793,088
Balance at Dec. 31, 2023	$ 131,792	148,696,200	(155,528,769)	(6,700,777)
Balance, shares at Dec. 31, 2023	131,793,088
Net loss				(12,832,316)
Increase of fair value of warrants in debt extinguishment				5,483,683
Balance at Jun. 30, 2024	$ 131,792	154,275,735	(168,361,085)	(13,953,558)
Balance, shares at Jun. 30, 2024	131,793,088
Balance at Dec. 31, 2023	$ 131,792	148,696,200	(155,528,769)	(6,700,777)
Balance, shares at Dec. 31, 2023	131,793,088
Net loss				(14,792,177)
Balance at Sep. 30, 2024	$ 131,792	154,650,064	(170,320,946)	(15,539,090)
Balance, shares at Sep. 30, 2024	131,793,088
Balance at Mar. 31, 2024	$ 131,792	150,158,398	(160,925,259)	(10,635,069)
Balance, shares at Mar. 31, 2024	131,793,088
Stock-based compensation expense		41,588		41,588
Net loss			(7,435,826)	(7,435,826)
Increase of fair value of warrants in debt extinguishment		4,075,749		4,075,749
Balance at Jun. 30, 2024	$ 131,792	154,275,735	(168,361,085)	(13,953,558)
Balance, shares at Jun. 30, 2024	131,793,088
Stock-based compensation expense		20,794		20,794
Net loss			(1,959,861)	(1,959,861)
Increase of fair value of warrants in debt extinguishment		344,098		344,098
Cancellation of warrants		9,437		9,437
Balance at Sep. 30, 2024	$ 131,792	$ 154,650,064	$ (170,320,946)	$ (15,539,090)
Balance, shares at Sep. 30, 2024	131,793,088

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (1,959,861)	$ (5,396,490)	$ (26,546,688)	$ (2,554,584)	$ (12,832,316)	$ (14,792,177)	$ (65,185,311)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	108,777		210,293			338,831	630,924
Amortization of right-of-use assets						303,806	286,816
Stock-based compensation	20,794		86,132			116,646	457,860
Interest and accretion on convertible notes and notes payable		2,733,939			5,125,620	6,230,294	11,038,400
Issuance of warrants for services							2,934,680
Change in fair value of contingent liabilities	(440,000)		1,678,000			57,000	(312,000)
Change in fair value of derivative liabilities			14,454,397				14,454,397
Loss on debt extinguishment	(59,843)	705,459	80,000		3,948,244	3,888,401	21,857,877
Loss on issuance of debt			3,974,993				6,352,562
Shares issued as part of the Confidential Settlement Agreement							153,600
Shares issued for services							168,000
Warrants issued as part of promissory note agreement							1,333,128
Borrowing costs						500,000
Change in operating assets and liabilities:
Accounts receivable and other receivables						58,201	24,120
Prepaid expenses						(26,737)	464,367
Inventory						(2,014)	116,547
Accounts payable and accrued expenses						1,033,824	1,852,865
Due to related parties						72,747	187,097
Operating lease liabilities						(303,806)	(286,816)
Net cash used in operating activities						(2,524,984)	(3,470,887)
Cash flows from financing activities:
Proceeds from issuance of Convertible Notes - OID, net of issuance cost							2,334,000
Proceeds from shares issued for exercise of warrants							265,216
Proceeds from notes payable						2,362,000	1,000,000
Repayments of notes payable and Convertible Notes - OID						(421,749)	(164,250)
Proceeds from agreement obligation						500,000
Net cash provided by financing activities						2,440,251	3,434,966
Net change in cash						(84,733)	(35,921)
Cash at beginning of period		$ 148,465		$ 510,865	$ 148,465	148,465	510,865	$ 510,865
Cash at end of period	$ 63,732		$ 474,944			63,732	474,944	148,465
Supplemental disclosure of cash flow information:
Derivative liabilities and debt discount issued in connection with convertible notes							25,555,092
Warrants and debt discount issued in connection with convertible notes							344,959
Settlement of notes payable with convertible notes							2,264,133
Increase of fair value of warrants in debt extinguishment							12,666,268	$ 12,666,268
Shares issued on conversion of convertible notes							$ 84,140

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended						6 Months Ended	9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (1,959,861)	$ (7,435,826)	$ (5,396,490)	$ (26,546,688)	$ (36,084,039)	$ (2,554,584)	$ (12,832,316)	$ (14,792,177)	$ (65,185,311)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 – DESCRIPTION OF BUSINESS Marizyme, Inc. (the “Company” or “Marizyme”) is a Nevada corporation originally incorporated on March 20, 2007, under the name SWAV Enterprises, Ltd. On September 6, 2010, the Company name was changed to GBS Enterprises Inc. and from 2010 to September 2018 the Company was in the software products and advisory services business for email and instant messaging applications. The Company divested that business between December 2016 and September 2018 and focused on the acquisition of life science technologies.  On March 21, 2018, the Company’s name was changed to Marizyme, Inc., to reflect the new life sciences focus. Marizyme’s common stock is currently quoted on the OTCQB tier of OTC Markets Group, Inc. under the symbol “MRZM”.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The Company’s unaudited condensed consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (“U.S. GAAP”) applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have an established source of revenues sufficient to cover its operating costs, which requires the Company to rely on investing and financing activities in order to continue as a going concern. The Company, since its inception, has incurred recurring operating losses and negative cash flows from operations and has an accumulated deficit of $ 170,320,946 155,528,769 29,122,609 21,673,945 63,732 148,465 Under the going concern assumption, an entity is ordinarily viewed as continuing its business for the foreseeable future with neither the intention or necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to the laws and regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business. The ability of the Company to continue as a going concern is dependent upon its ability to continue to successfully develop its intangible assets, meet its debt obligations until such time future profitable revenues are achieved, and raise funds beyond its working capital balance in order to finance future development of its intangible assets. During the next twelve months from the date the unaudited condensed consolidated financial statements were issued, the Company’s foreseeable cash requirements will relate to continuous operations of its business, maintaining its good standing and making the required filings with the Securities and Exchange Commission (the “SEC”), and the payment of expenses associated with its product development. The Company may experience a cash shortfall and be required to raise additional capital. Management intends to raise additional funds by way of a private or public offering. In July 2024, the Company executed a promissory note in favor of Qualigen Therapeutics, Inc., which had previously engaged in an agreement with the Company to advance the commercialization of DuraGraft™ (see Note 11). Under the terms of the promissory note, Qualigen lent the Company $ 1,250,000 1,027,400 The unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries: My Health Logic Inc (“My Health Logic” or “MHL”), Somahlution, Inc., and Somaceutica, Inc. (“Somaceutica”), (collectively, these three entities are referred to as – “Somahlution”), Marizyme Sciences, Inc. (“Marizyme Sciences”), and DuraGraft, Inc (“DuraGraft”). All intercompany transactions have been eliminated on consolidation. The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with U.S. GAAP. The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K/A filed with the SEC on February 6, 2025 (the “2023 Form 10-K/A”). The condensed consolidated balance sheet as of December 31, 2023 was derived from audited consolidated financial statements included in the 2023 Form 10-K/A but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company’s significant accounting policies are described in Note 1 to those consolidated financial statements. Interim results may not be indicative of the results that may be expected for the full year or any future periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary to fairly present the results of operations, financial condition, cash flows and stockholders’ equity (deficit) for the periods indicated. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, and contingent liabilities. Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below. ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. The carrying amounts of certain accounts and other receivables, accounts payable and accrued expenses, notes payable, and amounts due to related parties approximate fair value due to the short-term nature of these instruments. The fair value of lease obligations is determined using discounted cash flows based on the expected amounts and timing of the cash flows discounted using a market rate of interest adjusted for appropriate credit risk. Contingent Liabilities The contingent liabilities assumed on the acquisition of Somahlution in 2020 consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy. i. The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19 69.62 Nil 5.96 31,000 171,000 406,000 800,000 54,000 225,000 ii. The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6 409,000 228,000 1,262,000 466,000 3,586,000 3,358,000 iii. Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset – 20.6 Nil iv. The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21 78.93 Nil 5 1,823,000 1,823,000 Warrants The detachable warrants attached to the OID Convertible Notes (as such term is hereinafter defined, see Note 7) are classified as equity. These warrants were valued using the Black-Scholes pricing model. The following weighted average assumptions were used in the Black-Scholes model: a risk-free rate of 4.25 %, expected volatility of 349.95 %, expected dividend yield of $ Nil , and an expected life of 0.17 years. During the nine months ended September 30, 2024, the Company extended the maturity dates of certain OID Warrants (as such term is hereinafter defined, see Note 7), as part of modification of OID Convertible Notes that resulted in a substantive modification and extinguishment of old debt. As a result, the Company recognized an incremental fair value increase of $ 5,827,782 related to the change in the fair value of warrants. $ 4,778,950 of this amount exceeded the principal of the Convertible Notes and Goodwill, Intangible Assets and Impairment The Company’s Level 3 measurements include the fair value assessment of assets such as in-process research and development (“IPR&D”) intangibles, goodwill, and particularly when considering potential impairments. The significant unobservable inputs used in the fair value measurements of these assets primarily include management’s assumptions regarding future cash flows and discount rates. As part of the acquisition of Somahlution in 2020, the Company acquired goodwill attributed to the workforce and profitability of the acquired business. A residual method methodology was used to estimate the fair market value goodwill. A pre-tax discount rate based on weighted average cost of capital of 33.8 Additionally, as part of IPR&D 35.2 For impairment testing, the Company uses a discounted cash flow (“DCF”) model to estimate the fair value of IPR&D intangibles and goodwill. The key assumptions used in the DCF model include projected cash flows, discount rate and terminal value growth rate. These inputs are highly subjective and require significant management judgment. Changes in these assumptions could have a significant impact on the fair value and any resulting impairment charge. The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Marizyme measures the following financial instruments at fair value on a recurring basis. As of September 30, 2024, and December 31, 2023, the fair values of these financial instruments were as follows: SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS September 30, 2024 Level 1 Level 2 Level 3 Fair Value Hierarchy September 30, 2024 Level 1 Level 2 Level 3 Liabilities Contingent liabilities $ - $ - $ 5,463,000 Total $ - $ - $ 5,463,000 December 31, 2023 Level 1 Level 2 Level 3 Fair Value Hierarchy December 31, 2023 Level 1 Level 2 Level 3 Liabilities Contingent liabilities $ - $ - $ 5,406,000 Total $ - $ - $ 5,406,000 The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs: SCHEDULE OF LIABILITIES FAIR VALUE MEASURED Contingent Liabilities Balance at December 31, 2023 $ 5,406,000 Change in fair value of contingent liabilities 57,000 Balance at September 30, 2024 $ 5,463,000 Research and Development Expenses and Accruals All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, and employee benefits, for individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of DuraGraft, and costs related to manufacturing DuraGraft for clinical trials. The Company has entered into various research and development contracts with various organizations. Payments of these activities are based on the terms of the individual agreements which matches to the pattern of costs incurred. Payments made in advance are reflected in the accompanying condensed consolidated balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be required in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Stock-Based Compensation Stock-based compensation expense for employees and directors is recognized in the unaudited condensed consolidated statements of operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, the Company estimates the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. The Company estimates the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (“RSU”) equity awards, the Company estimates the grant date fair value using its closing stock price on the date of grant. The Company recognizes the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. The Company recognizes the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which share-based awards vest. New Accounting Standards and Updates from the Securities and Exchange Commission In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. Convertible instruments that continue to be subject to separation models are (i) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (ii) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company has fully adopted ASU 2020-06 as of January 1, 2023, and this adoption does not have a material impact on the way the Company is accounting for its debt.

LEASES

LEASES	9 Months Ended
	Sep. 30, 2024
Leases
LEASES	NOTE 4 – LEASES On December 11, 2020, the Company entered into a five-and-a-half-year lease agreement 10,300 10,800 2.5 12,000 Effective April 1, 2022, the Company amended its lease agreement for administrative office and laboratories to add an additional 3,053 15,641 16,032 2.5 12,000 17,500 1.83 The assets and liabilities from the lease were recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the discount rate of 3.95 The total rent expense for the three and nine months ended September 30, 2024 was $ 129,416 290,474 81,502 274,004 The following table summarizes supplemental condensed consolidated balance sheet information related to the operating leases as of September 30, 2024, and December 31, 2023: SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITIES September 30, 2024 December 31, 2023 Operating lease right-of-use assets $ 797,405 $ 1,101,211 Operating lease liabilities, current $ 442,221 $ 434,082 Operating lease liabilities, non-current 355,184 667,129 Total operating lease liabilities $ 797,405 $ 1,101,211 As of September 30, 2024, the maturities of the lease liabilities for the periods ending December 31 are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2024 $ 108,521 2025 444,934 2026 266,034 Total lease payments 819,489 Less: Present value discount (22,084 ) Total $ 797,405

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 5 – INTANGIBLE ASSETS Krillase As part of the asset acquisition of ACB Holding AB, Reg. No. 559119-5762, completed on September 12, 2018, Marizyme acquired all rights, titles, and interest in the Krillase technology, a group of intangible assets valued at $ 28,600,000 At December 31, 2023, management determined that the carrying value of Krillase exceeded its estimated recoverable amount of $ Nil 4,250,000 There have been no DuraGraft As part of Somahlution acquisition in 2020, Marizyme purchased $ 18,170,000 At December 31, 2023, management determined that the carrying value of DuraGraft intangible assets exceeded its recoverable amount. Impairment of $ 2,442,000 14,241,384 no My Health Logic As part of the My Health Logic acquisition in 2021 6,600,000 5,777,720 no Additionally, as part of the My Health Logic acquisition in 2021 1,774,656 1,774,656 SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSE   September 30, 2024   Gross Carrying Amount Accumulated Amortization Net Carrying Amount Patents in process $ 122,745 $ - $ 122,745 DuraGraft patent 5,256,000 (1,684,614 ) 3,571,386 DuraGraft - Distributor relationship 308,000 (128,333 ) 179,667 DuraGraft IPR&D - Cyto Protectant Life Sciences 10,164,000 - 10,164,000 Total intangible assets, net $ 15,850,745 $ (1,812,947 ) $ 14,037,798 December 31, 2023 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Krillase intangible assets $ 4,250,000 $ - $ (4,250,000 ) $ - Patents in process 122,745 - - 122,745 DuraGraft patent 5,256,000 (1,381,383 ) - 3,874,617 DuraGraft - Distributor relationship 308,000 (105,233 ) - 202,767 DuraGraft IPR&D - Cyto Protectant Life Sciences 12,606,000 - (2,442,000 ) 10,164,000 My Health Logic - Trade name 450,000 (65,090 ) (384,910 ) - My Health Logic - Biotechnology 4,600,000 (547,941 ) (4,052,059 ) - My Health Logic - Software 1,550,000 (209,249 ) (1,340,751 ) - Total intangible assets, net $ 29,142,745 $ (2,308,896 ) $ (12,469,720 ) $ 14,364,129 SCHEDULE OF GOODWILL Goodwill DuraGraft My Health Logic Total Balance, December 31, 2023 and September 30, 2024 $ 5,416,000 $ - $ 5,416,000 The following changes to the Company’s intangible assets had taken place in the periods indicated: SCHEDULE OF INTANGIBLE ASSETS Balance, December 31, 2022 $ 27,675,020 Impairment (12,469,720 ) Amortization expense (841,171 ) Balance, December 31, 2023 14,364,129 Amortization expense (326,331 ) Balance, September 30, 2024 $ 14,037,798 Future amortizations for DuraGraft intangible assets for the next five years will be $ 435,108 1,575,512

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Sep. 30, 2024
Notes Payable
NOTES PAYABLE	NOTE 6 – NOTES PAYABLE a) On October 23, 2023, the Company issued a note payable to Hub International for $ 165,469 8 August 23, 2024 Nil 130,122 b) On December 28, 2022, the Company issued a promissory note to Hexin for the principal amount of $ 750,000 20 64,133 814,133 9,578,040 c) On February 2, 2023, the Company issued an unsecured promissory note to Walleye Opportunities Master Fund Ltd. (the “Walleye Promissory Note”) for $ 1,000,000 May 7, 2023 1,250,000 1,000,000 1,250,000 250,000 1,250,000 14,705,890 d) As part of the My Health Logic acquisition, completed in November 2021, Marizyme assumed an aggregate of $ 468,137 9 278,678 5,868 17,010 5,344 23,710 264,535 252,223 ). e) As of September 30, 2024, the Company has outstanding borrowings under notes payable to Mr. Richmond in the principal amount of $ 441,000 (December 31, 2023 - $ 151,000 ) f) As of September 30, 2024, the Company has outstanding borrowings under a note payable to Santander Bank: Sullivan & Worcester LLP in the principal amount of $ 515,000 (December 31, 2023 - $ 65,000 ) g) As of September 30, 2024, the Company has outstanding borrowings under a note payable to Commas International Holding, LLC in the principal amount of $ 170,000 (December 31, 2023 - $ Nil ) h) As of September 30, 2024, the Company has outstanding borrowings under a note payable to Dr. Vithalbhai Dhaduk in the principal amount of $ 52,000 (December 31, 2023 - $ Nil ) i) On July 12, 2024, the Company received $ 1,250,000 18 47,446 Nil

CONVERTIBLE PROMISSORY NOTES AN

CONVERTIBLE PROMISSORY NOTES AND WARRANTS	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
CONVERTIBLE PROMISSORY NOTES AND WARRANTS	NOTE 7 - CONVERTIBLE PROMISSORY NOTES AND WARRANTS From May 2021 to August 2022, the Company conducted a private placement (the “Units Private Placement”) of units (the “Units”) consisting of 10% secured convertible promissory notes (the “Convertible Notes”) and accompanying warrants (the “Class C Warrants”), as were modified or amended from time to time. In 2021, the Company issued an aggregate of 4,260,594 6,692,765 4,180,071 6,500,743 In 2023, the Company amended the conversion price of the Convertible Notes and the exercise price of the Class C Warrants to $ 0.10 The Company determined that the terms of the new securities were substantially different from the original securities, and, as such the transaction was accounted for as an extinguishment of debt and the new securities accounted for as a new debt issuance. As a result of this substantial modification, a total of 8,269,237 190,584,260 12,666,268 21,777,877 Additionally, in 2023 due to the non-repayment of the initial principal amount of $ 1,000,000 May 7, 2023 the Company also defaulted under the Convertible Notes on the same date. As the result, the Company accreted a default amount of $6,791,185 to the value of the Convertible Notes in 2023. Additionally, in 2023, the Company issued an aggregate of 4,207,828 344,959 9,340,774 During the three and nine months ended September 30, 2024, the Company amended certain Convertible Notes, extending their original maturity dates in 2024 by one year from their respective original maturity dates. In connection with the extension of the maturity dates for the outstanding Convertible Notes, the Company executed a substantial modification that led to the extinguishment of the existing Convertible Notes and the issuance of new Convertible Notes. This modification resulted in a gain on extinguishment of $ 890,549 21,777,877 During the three and nine months ended September 30, 2024, the Company recognized interest and accretion expense of $ 433,868 1,260,775 529,596 3,265,387 The Company determined that the optional conversion feature attached to the Convertible Notes did not meet the definition of derivative liability and that the detachable warrants issued did not meet the definition of a liability and therefore was accounted for as an equity instrument. The following table summarizes supplemental balance sheet information related to the convertible notes, net of debt discount outstanding, as of September 30, 2024 and December 31, 2023: SCHEDULE OF CONVERTIBLE NOTES Balance, December 31, 2022 $ 2,751,633 Issuance costs - Debt accretion - Settlement of debt - Issuance of convertible notes - Debt accretion on Original securities 1,835,741 Debt extinguishment (4,587,374 ) Convertible notes issued - new securities 19,403,385 Debt discount (344,959 ) Debt interest and accretion on new securities 1,429,646 Mandatory default amount 6,835,105 Conversion of debt (9,509,505 ) Extinguishment of debt (10,276,925 ) Convertible notes issued with extended maturity date 8,791,729 Balance, December 31, 2023 16,328,476 Debt interest and accretion 1,260,775 Extinguishment of debt (6,160,552 ) Convertible notes issued with extended maturity date 5,270,001 Balance, September 30, 2024 $ 16,698,700 SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT September 30, 2024 December 31, 2023 Convertible notes - total principal $ 17,272,077 $ 17,516,865 Unamortized issuance costs and discount (573,377 ) (1,188,389 ) Convertible Notes, Net of Debt Discount $ 16,698,700 $ 16,328,476 September 30, 2024 December 31, 2023 Current portion $ 16,698,700 $ 16,328,476 Non-current portion - - Convertible Notes, Net of Debt Discount $ 16,698,700 $ 16,328,476 2023 Convertible Notes and Warrants In 2023, the Company conducted five separate closings (the “2023 OID Units Closings”) of a private placement of up to $ 10,000,000 100,000,000 15 0.10 125 0.10 125 0.20 Pursuant to the 2023 OID Units Closings, the Company issued 69,876,060 5,404,452 The Company determined that the optional conversion feature attached to the OID Convertible Notes did not meet the definition of derivative liability and that the detachable warrants originally issued met the definition of a liability and therefore was accounted for as a derivative liability instrument. The warrants were fair valued at $ 12,292,635 6,888,475 795,934 11,496,701 11,496,701 During the nine months ended September 30, 2024, the Company extended the maturity date of certain OID Convertible Notes. While some extensions were deemed minor, the majority of the extended contracts were deemed substantive. This triggered the extinguishment of the existing OID Convertible Notes and the issuance of new OID Convertible Notes. Additionally, the detachable warrants attached to the OID Convertible Notes had their maturity extended by two years. As a result, for the nine months ended September 30, 2024, the Company recognized an incremental fair value increase of $ 5,827,782 as a change in the fair value of warrants. $ 4,778,950 of this amount exceeded the principal of the Convertible Notes and was recognized as a loss on debt extinguishment in the condensed consolidated statements of operations for the nine months ended September 30, 2024 (September 30, 2023 - $ Nil ). During the three and nine months ended September 30, 2024, the Company recognized interest and accretion expense of $ 613,186 4,885,930 843,699 993,785 The following table summarizes supplemental balance sheet information related to the OID Convertible Notes, net of debt discount outstanding, as of September 30, 2024 and December 31, 2023: SCHEDULE OF CONVERTIBLE NOTES OID Convertible Notes, Net of Debt Discount Balance, December 31, 2022 $ - Issuance of convertible notes 6,987,606 Issuance cost (1,583,154 ) Debt discount (5,404,452 ) Debt accretion 2,694,256 Balance, December 31, 2023 2,694,256 Debt accretion 4,885,930 Extinguishment of debt (7,264,572 ) Settlement of debt (109,437 ) Convertible note issued with extended maturity date 6,215,741 Balance, September 30, 2024 $ 6,421,918 SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT September 30, 2024 December 31, 2023 Convertible notes - total principal $ 6,841,769 $ 6,987,606 Unamortized issuance costs and discount (419,851 ) (4,293,350 ) Convertible Notes, Net of Debt Discount $ 6,421,918 $ 2,694,256 September 30, 2024 December 31, 2023 Current portion $ 6,421,918 $ 2,694,256 Non-current portion - - Convertible Notes, Net of Debt Discount $ 6,421,918 $ 2,694,256 2023 Convertible Notes Terms The OID Convertible Notes mature nine months from the date of the OID Units Initial Closing and accrue 10% of interest per annum on the outstanding principal amount. The OID Convertible Notes are unsecured and subordinated to any senior indebtedness of the Company. The OID Convertible Notes’ principal and accrued interest may generally be converted at any time at a conversion price of $0.10 per share, subject to adjustment, at the option of the holder, into shares of common stock, subject to certain limitations: (i) conversion would not cause the holder to beneficially own more than 4.99% of the Company’s common stock, or more than 9.99% if the holder beneficially owns more than 4.99% of common stock based on ownership of equity securities of the Company other than the OID Convertible Notes or the respective warrants; and (ii) the Company’s articles of incorporation have been amended to increase the number of authorized shares of common stock to a sufficient amount to permit the full conversion of the OID Convertible Notes (the “Capital Event Amendment”). 2023 Warrants Terms The Class E Warrants and Class F Warrants are generally exercisable for a period from the date of the Capital Event Amendment until five years from the date of issue. The exercise right is subject to a similar beneficial ownership limitation that applies to conversion of the OID Convertible Notes above, i.e., exercise is permitted only if it would not cause the holder to beneficially own more than 4.99% of the Company’s common stock, or more than 9.99% if the holder beneficially owns more than 4.99% of common stock based on ownership of equity securities of the Company other than the OID Convertible Notes or the Class E Warrants and Class F Warrants.

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
STOCKHOLDERS’ EQUITY (DEFICIT)	NOTE 8 – STOCKHOLDERS’ EQUITY (DEFICIT) a) Preferred stock The Company is authorized to issue a total number of 25,000,000 0.001 no b) Common stock The Company is authorized to issue a total number of 2,000,000,000 0.001 As of September 30, 2024, there were 131,793,088 131,793,088 c) Options On May 18, 2021, the Company’s Board of Directors approved the Marizyme, Inc. Amended and Restated 2021 Stock Incentive Plan (“SIP”). The SIP incorporates stock options issued prior to May 18, 2021. The SIP authorized 5,300,000 On December 27, 2022, the Board of Directors requested that stockholders ratify an amendment to the SIP to increase the maximum number of shares of common stock available for issuance pursuant to awards granted under the SIP by 1,900,000 7,200,000 4,304,724 2,924,057 During the three and nine months ended September 30, 2024, the Company granted $ Nil Nil The summary of option activity for the six months ended September 30, 2024, is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of Options Weighted Average Exercise Price Weighted Average Contractual Life Total Intrinsic Value Outstanding at December 31, 2022 3,925,943 $ 1.33 6.06 $ - Granted/forfeited - - - - Outstanding at December 31, 2023 3,925,943 1.33 5.06 - Forfeited (211,667 ) 1.64 - - Expired (1,168,333 ) 1.08 - Outstanding at September 30, 2024 2,545,943 1.42 6.07 - Exercisable at September 30, 2024 2,485,943 $ 1.41 6.04 $ - As of September 30, 2024, the Company had the following options outstanding: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Number of Options Outstanding Number of Options Exercisable Weighted Average Remaining Contractual Years Intrinsic Value $ 1.01 890,943 890,943 4.55 $ - 1.25 415,000 415,000 6.40 - 1.37 200,000 200,000 5.88 - 1.75 800,000 770,000 7.16 - 2.20 240,000 210,000 7.69 - $ 1.44 2,545,943 2,485,943 6.07 $ - d) Restricted share units During the year ended December 31, 2021, the Company granted restricted share awards totaling 350,000 No Nil Nil The following performance conditions attached to the restricted share awards were achieved: ● The Company will raise financing for the gross proceeds that equal or exceed $ 5,000,000 ● The Company will complete valuation reports for acquisition of Somahlution and My Health Logic. e) Warrants As of September 30, 2024 and December 31, 2023, there were 633,542,434 636,483,634 SCHEDULE OF WARRANTS OUTSTANDING Number Weighted Average Price Balance, December 31, 2022 20,048,497 $ 2.64 Warrants modified pursuant to debt extinguishment (Note 7) 355,577,447 0.1 Issued pursuant to debt agreements (Note 7) 183,560,497 0.15 Issued 79,949,352 0.11 Exercised (2,652,159 ) 0.1 Balance, December 31, 2023 636,483,634 $ 0.12 Cancelled (2,941,200 ) 0.15 Balance, September 30, 2024 633,542,434 $ 0.12 The detachable warrants attached to the OID Convertible Notes (see Note 7) are classified as equity. These warrants were valued using the Black-Scholes pricing model. During the three and nine months ended September 30, 2024, the Company extended the maturity dates of certain OID Warrants (see Note 7), resulting in a series of substantive modifications. As a result, the Company recognized an incremental fair value increase of $ 5,827,782 related to the change in the fair value of warrants. $ 4,778,950 of this amount exceeded the principal of the Convertible Notes and was recognized as a loss on debt extinguishment in the condensed consolidated statement of operations for the nine months ended September 30, 2024 f) Stock-based compensation During the three and nine months ended September 30, 2024, the Company recorded $ 20,794 116,646 86,123 457,860

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS At September 30, 2024, the Company owed an aggregate of $ 302,900 230,153 For the three and nine months ended September 30, 2024, the Company incurred $ 277,000 882,000 404,750 1,214,250 302,900 7,653 During the three and nine months ended September 30, 2024, the Company also incurred $ 208,500 632,500 257,750 773,250 292,500 222,500 Additionally, as part of the Somahlution acquisition in 2020, the Company recorded a prepaid royalty to the shareholders of Somahlution. The former primary beneficial owner is Dr. Vithal Dhaduk, currently a director, and significant shareholder of the Company. During the three and nine months ended September 30, 2024, the Company accrued $ Nil 1,957 13,014 211,262 During the year ended December 31, 2023, the Company and stockholders of Somahlution agreed to reduce the prepaid royalty balance by 50% or by $ 151,000 120,500 122,457

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 – COMMITMENTS AND CONTINGENCIES Contingencies As part of the DuraGraft Acquisition, completed on July 31, 2020, the Company entered into the Agreement with Somahlution stockholders, whereby Marizyme is legally obligated to pay royalties on all net sales for Somahlution, Inc. The royalties associated with the Agreement are calculated as follows: Royalties on U.S. sales equal to: Royalties on U.S. sales equal to: ● 5 ● 4 ● 2 Royalties on sales outside of the U.S.: ● 6 ● 4 ● 2 The royalties are in perpetuity. During the three and nine months ended September 30, 2024, the Company had not earned any revenues from Krillase; however, the Company did incur sales of the DuraGraft products outside of the U.S., of which $ Nil 1,957 Upon receiving FDA clearance for the DuraGraft product and insurance reimbursement approval on the products pursuant to section 2(b) of the Asset Purchase Agreement dated December 15, 2019, the Company will: ● Issue performance warrants with a strike price determined based on the average of the closing prices of the Company’s common stock for the 30 calendar days following the date of the public announcement of the FDA approval; and ● Upon liquidation of all or substantially all of the assets relating to DuraGraft, the Company will pay 15 20 c. The Company has entered into arrangements for office and laboratories spaces. As of September 30, 2024, minimum lease payments in relation to lease commitments are payable as described in Note 4.

AGREEMENT OBLIGATION

AGREEMENT OBLIGATION	9 Months Ended
	Sep. 30, 2024
Agreement Obligation
AGREEMENT OBLIGATION	NOTE 11 – AGREEMENT OBLIGATION In April 2024, the Company entered into an agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) to support the commercialization of DuraGraft™. Under the Agreement, Qualigen paid the Company an exclusivity fee of $ 200,000 500,000 In return, Qualigen expects an investment return equal to two times (2x) the Funding Amount (the “Investment Return”). Upon the commercial launch of DuraGraft™ in the United States, the Company is obligated to pay Qualigen up to a cumulative total equal to the Investment Return, calculated at 33 500,000 As part of the agreement, the Company established a wholly owned subsidiary, DuraGraft, during the nine months ended September 30, 2024, to facilitate the product’s commercialization. The Exclusivity Fee was recognized as other income in the condensed consolidated statement of operations for the nine months ended September 30, 2024, as it represented payment for exclusive negotiation rights. The Funding Amount was accounted for as a debt liability, due to the significant continuing involvement by the Company and the limitation on Qualigen’s rate of return. The obligation to repay the Investment Return amount in case of agreement cancellation further supports this classification. Given the uncertainty in the timing and amount of future revenue streams, the effective interest rate could not be determined. Therefore, the difference of $ 500,000 1,000,000

RESTATEMENT OF PREVIOUSLY ISSUE

RESTATEMENT OF PREVIOUSLY ISSUED UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]
RESTATEMENT OF PREVIOUSLY ISSUED UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	NOTE 12 – RESTATEMENT OF PREVIOUSLY ISSUED UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS In March 2025, the Board of Directors and management, upon the recommendation of the Audit Committee of the Board of Directors, concluded that certain accounting errors identified in the Company’s financial statements for interim periods ended March 31, 2024 and June 30, 2024, required restatement. As a result, the Company amended those unaudited condensed consolidated financial statements for the interim periods ended March 31, 2024, and June 30, 2024, within this Form 10-Q for the nine months ended September 30, 2024. The Company has not filed, and does not intend to file, amendments to the previously filed Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024, but instead is restating its unaudited interim condensed consolidated financial statements in this Form 10-Q for the nine months ended September 30, 2024. The Company evaluated the materiality of these errors both qualitatively and quantitatively in accordance with Staff Accounting Bulletin (“SAB”) No. 99, “Materiality”, and SAB No. 108, “Considering the Effects of Prior Year Misstatements on Currently Issued Financial Statements”. Based on this evaluation, the Company determined that the effect of these corrections was material to the financial statements for the interim periods ended June 30, 2024 and September 30, 2024. Consequently, the Company restated these financial statements in accordance with Accounting Standards Codification 250, “Accounting Changes and Error Corrections.” The errors resulted from a material weakness in the proper technical analysis of debt/equity transactions. The restatements for the Company’s previously issued financial statements as of and for the quarterly periods ended March 31, 2024 and June 30, 2024, included the following: 1. During the three and nine months ended September 30, 2024, the Company amended certain Convertible Notes – Units Private Placement and Convertible Notes - OID, extending their original maturity dates in 2024 by one year from their respective original maturity dates (see Note7) ● A difference between the reacquisition price of the debt and the net carrying amount of the extinguished debt. ● In the original filing, this difference between the reacquisition price of the debt and the net carrying amount of the extinguished debt was incorrectly recorded as part of the convertible debt discount to be amortized over the remaining life of the notes. ● In the amendments to the previously filed Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024 2. Additionally, following the recalculation of the carrying value of the notes after extinguishment, the fair market value of the warrants attached to the Convertible Notes – Units Private Placement and Convertible Notes - OID increased. This adjustment impacted the Company’s additional paid-in capital and contributed to the loss on extinguishment recognized in the period. The restatement had no impact on total net cash flows from operating, investing, or financing activities. SCHEDULE OF RESTATEMENT FINANCIAL STATEMENTS Consolidated Balance Sheet – as March 31, 2024 Originally Reported Restatement Adjustment As As of March 31, 2024 (Unaudited) Originally Reported Restatement Adjustment As LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT Current portion of Convertible Notes - Units Private Placement $ 15,807,061 $ 409,974 $ 16,217,035 Current portion of Convertible Notes - OID $ 5,448,468 $ (607,569 ) $ 4,840,899 Total current liabilities $ 25,847,800 $ (197,595 ) $ 25,650,205 Total liabilities $ 32,402,707 $ (197,595 ) $ 32,205,112 Stockholders’ deficit: Additional paid-in capital $ 146,598,185 $ 3,560,213 $ 150,158,398 Accumulated deficit $ (157,562,641 ) $ (3,362,618 ) $ (160,925,259 ) Consolidated Statement of Operations and Comprehensive Loss - Three Months Ended March 31, 2024 Originally Reported Restatement Adjustment As Three months ended March 31, 2024 (Unaudited) Originally Reported Restatement Adjustment As Interest and accretion expenses $ (4,161,830 ) $ 1,427,891 $ (2,733,939 ) Loss on debt extinguishment $ (107,370 ) $ (598,089 ) $ (705,459 ) Total other income (expense) $ (4,854,200 ) $ 829,802 $ (4,024,398 ) Net loss $ (6,226,292 ) $ 829,802 $ (5,396,490 ) Loss per share – basic and diluted $ (0.05 ) $ 0.01 $ (0.04 ) Consolidated Statement of Stockholders’ Deficit – Three Months Ended March 31, 2024 Originally Reported Restatement Adjustment As Three month ended March 31, 2024 (Unaudited) Originally Reported Restatement Adjustment As Increase of fair value of warrants in debt extinguishment $ - $ (1,407,934 ) $ (1,407,934 ) Net loss $ (6,226,292 ) $ 829,802 $ (5,396,490 ) Total stockholders’ deficit $ (10,832,664 ) $ 197,595 $ (10,635,069 ) Consolidated Statement of Cash Flows – Three Months Ended March 31, 2024 Originally Reported Restatement Adjustment As Three months ended March 31, 2024 (Unaudited) Originally Reported Restatement Adjustment As Net loss $ (6,226,292 ) $ 829,802 $ (5,396,490 ) Interest and accretion on convertible notes and notes payable $ 4,161,830 $ (1,427,891 ) $ 2,733,939 Loss on debt extinguishment $ 107,370 $ 598,089 $ 705,459 Consolidated Balance Sheet – as June 30, 2024 Originally Reported Restatement Adjustment As As of June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT Current portion of Convertible Notes - Units Private Placement $ 17,022,717 $ (482,186 ) $ 16,540,531 Current portion of Convertible Notes - OID $ 990,636 $ 5,055,776 $ 6,046,412 Total current liabilities $ 23,551,638 $ 4,573,590 $ 28,125,228 Total liabilities $ 30,914,541 $ 4,573,590 $ 35,488,131 Stockholders’ deficit: Additional paid-in capital $ 152,123,457 $ 2,152,278 $ 154,275,735 Accumulated deficit $ (161,635,217 ) $ (6,725,868 ) $ (168,361,085 ) Consolidated Statement of Operations and Comprehensive Loss - Three Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Three months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Interest and accretion expenses $ (2,938,416 ) $ 546,735 $ (2,391,681 ) Gain (loss) on debt extinguishment $ 667,200 $ (3,909,985 ) $ (3,242,785 ) Total other income (expense) $ (2,483,216 ) $ (3,363,250 ) $ (5,846,466 ) Net loss $ (4,072,576 ) $ (3,363,250 ) $ (7,435,826 ) Loss per share – basic and diluted $ (0.03 ) $ ( 0.03 ) $ (0.06 ) Consolidated Statement of Stockholders’ Deficit – Three Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Three months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Increase of fair value of warrants in debt extinguishment $ - $ 4,075,749 $ 4,075,749 Modification of warrants $ 5,483,684 $ (5,483,684 ) - Net loss $ (4,072,576 ) $ (3,363,250 ) $ (7,435,826 ) Total stockholders’ deficit $ (9,379,968 ) $ (4,573,590 ) $ (13,953,558 ) Consolidated Statement of Operations and Comprehensive Loss - Six Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Six months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Interest and accretion expenses $ (7,100,246 ) $ 1,974,626 $ (5,125,620 ) Gain on debt extinguishment $ 559,830 $ (4,508,074 ) $ (3,948,244 ) Total other income (expense) $ (7,337,416 ) $ (2,533,448 ) $ (9,870,864 ) Net loss $ (10,298,868 ) $ (2,533,448 ) $ (12,832,316 ) Loss per share – basic and diluted $ (0.08 ) $ ( 0.02 ) $ (0.10 ) Consolidated Statement of Stockholders’ Deficit – Six Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Six months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Increase of fair value of warrants in debt extinguishment $ - $ 5,483,683 $ 5,483,683 Modification of warrants $ 5,483,684 $ (5,483,684 ) - Net loss $ (10,298,868 ) $ (2,533,448 ) $ (12,832,316 ) Total stockholders’ deficit $ (9,379,968 ) $ (4,573,590 ) $ (13,953,558 ) Consolidated Statement of Cash Flows – Six Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Six months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Net loss $ (10,298,868 ) $ (2,533,448 ) $ (12,832,316 ) Interest and accretion on convertible notes and notes payable $ 7,100,246 $ (1,974,626 ) $ 5,125,620 Gain (loss) on debt extinguishment $ (559,830 ) $ 4,508,074 $ 3,948,244

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 - SUBSEQUENT EVENTS The Company has evaluated events that occurred through March 5, 2025, the date that the condensed consolidated financial statements were issued, and determined that except than as set forth below, there have been no events that have occurred that would require adjustments to the Company’s disclosures in the condensed consolidated financial statements. 1) During the final quarter of the fiscal year ended December 31, 2024, the Company extended the maturity date of three OID Convertible Notes, originally maturing on December 21, 2024, by one year. Additionally, the maturity of the detachable warrants associated with these OID Convertible Notes was extended by two years. 2) During the final quarter of the fiscal year ended December 31, 2024, the Company repaid a short-term loan under a note payable to Dr. Vithalbhai Dhaduk, with a principal amount of $ 52,000 3) In December 2024, the Company secured additional funding totaling $ 707,404 18 4) On January 21, 2025, the Company terminated an employment agreement with Catherine Pachuk, the Chief Scientific Officer and Executive Vice President of the Company.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries: My Health Logic Inc (“My Health Logic” or “MHL”), Somahlution, Inc., and Somaceutica, Inc. (“Somaceutica”), (collectively, these three entities are referred to as – “Somahlution”), Marizyme Sciences, Inc. (“Marizyme Sciences”), and DuraGraft, Inc (“DuraGraft”). All intercompany transactions have been eliminated on consolidation. The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with U.S. GAAP. The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K/A filed with the SEC on February 6, 2025 (the “2023 Form 10-K/A”). The condensed consolidated balance sheet as of December 31, 2023 was derived from audited consolidated financial statements included in the 2023 Form 10-K/A but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company’s significant accounting policies are described in Note 1 to those consolidated financial statements. Interim results may not be indicative of the results that may be expected for the full year or any future periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary to fairly present the results of operations, financial condition, cash flows and stockholders’ equity (deficit) for the periods indicated. Except as otherwise disclosed, all such adjustments are of a normal recurring nature.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, and contingent liabilities.
Fair Value Measurements	Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below. ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. The carrying amounts of certain accounts and other receivables, accounts payable and accrued expenses, notes payable, and amounts due to related parties approximate fair value due to the short-term nature of these instruments. The fair value of lease obligations is determined using discounted cash flows based on the expected amounts and timing of the cash flows discounted using a market rate of interest adjusted for appropriate credit risk.
Contingent Liabilities	Contingent Liabilities The contingent liabilities assumed on the acquisition of Somahlution in 2020 consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy. i. The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19 69.62 Nil 5.96 31,000 171,000 406,000 800,000 54,000 225,000 ii. The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6 409,000 228,000 1,262,000 466,000 3,586,000 3,358,000 iii. Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset – 20.6 Nil iv. The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21 78.93 Nil 5 1,823,000 1,823,000
Warrants	Warrants The detachable warrants attached to the OID Convertible Notes (as such term is hereinafter defined, see Note 7) are classified as equity. These warrants were valued using the Black-Scholes pricing model. The following weighted average assumptions were used in the Black-Scholes model: a risk-free rate of 4.25 %, expected volatility of 349.95 %, expected dividend yield of $ Nil , and an expected life of 0.17 years. During the nine months ended September 30, 2024, the Company extended the maturity dates of certain OID Warrants (as such term is hereinafter defined, see Note 7), as part of modification of OID Convertible Notes that resulted in a substantive modification and extinguishment of old debt. As a result, the Company recognized an incremental fair value increase of $ 5,827,782 related to the change in the fair value of warrants. $ 4,778,950 of this amount exceeded the principal of the Convertible Notes and
Goodwill, Intangible Assets and Impairment	Goodwill, Intangible Assets and Impairment The Company’s Level 3 measurements include the fair value assessment of assets such as in-process research and development (“IPR&D”) intangibles, goodwill, and particularly when considering potential impairments. The significant unobservable inputs used in the fair value measurements of these assets primarily include management’s assumptions regarding future cash flows and discount rates. As part of the acquisition of Somahlution in 2020, the Company acquired goodwill attributed to the workforce and profitability of the acquired business. A residual method methodology was used to estimate the fair market value goodwill. A pre-tax discount rate based on weighted average cost of capital of 33.8 Additionally, as part of IPR&D 35.2 For impairment testing, the Company uses a discounted cash flow (“DCF”) model to estimate the fair value of IPR&D intangibles and goodwill. The key assumptions used in the DCF model include projected cash flows, discount rate and terminal value growth rate. These inputs are highly subjective and require significant management judgment. Changes in these assumptions could have a significant impact on the fair value and any resulting impairment charge. The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Marizyme measures the following financial instruments at fair value on a recurring basis. As of September 30, 2024, and December 31, 2023, the fair values of these financial instruments were as follows: SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS September 30, 2024 Level 1 Level 2 Level 3 Fair Value Hierarchy September 30, 2024 Level 1 Level 2 Level 3 Liabilities Contingent liabilities $ - $ - $ 5,463,000 Total $ - $ - $ 5,463,000 December 31, 2023 Level 1 Level 2 Level 3 Fair Value Hierarchy December 31, 2023 Level 1 Level 2 Level 3 Liabilities Contingent liabilities $ - $ - $ 5,406,000 Total $ - $ - $ 5,406,000 The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs: SCHEDULE OF LIABILITIES FAIR VALUE MEASURED Contingent Liabilities Balance at December 31, 2023 $ 5,406,000 Change in fair value of contingent liabilities 57,000 Balance at September 30, 2024 $ 5,463,000
Research and Development Expenses and Accruals	Research and Development Expenses and Accruals All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, and employee benefits, for individuals involved in research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company’s ongoing clinical trials of DuraGraft, and costs related to manufacturing DuraGraft for clinical trials. The Company has entered into various research and development contracts with various organizations. Payments of these activities are based on the terms of the individual agreements which matches to the pattern of costs incurred. Payments made in advance are reflected in the accompanying condensed consolidated balance sheets as prepaid expenses. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be required in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense for employees and directors is recognized in the unaudited condensed consolidated statements of operations based on estimated amounts, including the grant date fair value and the expected service period. For stock options, the Company estimates the grant date fair value using a Black-Scholes valuation model, which requires the use of multiple subjective inputs including estimated future volatility, expected forfeitures and the expected term of the awards. The Company estimates the expected future volatility based on the stock’s historical price volatility. The stock’s future volatility may differ from the estimated volatility at the grant date. For restricted stock unit (“RSU”) equity awards, the Company estimates the grant date fair value using its closing stock price on the date of grant. The Company recognizes the effect of forfeitures in compensation expense when the forfeitures occur. The estimated forfeiture rates may differ from actual forfeiture rates which would affect the amount of expense recognized during the period. The Company recognizes the value of the awards over the awards’ requisite service or performance periods. The requisite service period is generally the time over which share-based awards vest.
New Accounting Standards and Updates from the Securities and Exchange Commission	New Accounting Standards and Updates from the Securities and Exchange Commission In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. Convertible instruments that continue to be subject to separation models are (i) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (ii) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company has fully adopted ASU 2020-06 as of January 1, 2023, and this adoption does not have a material impact on the way the Company is accounting for its debt.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS	Marizyme measures the following financial instruments at fair value on a recurring basis. As of September 30, 2024, and December 31, 2023, the fair values of these financial instruments were as follows: SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS September 30, 2024 Level 1 Level 2 Level 3 Fair Value Hierarchy September 30, 2024 Level 1 Level 2 Level 3 Liabilities Contingent liabilities $ - $ - $ 5,463,000 Total $ - $ - $ 5,463,000 December 31, 2023 Level 1 Level 2 Level 3 Fair Value Hierarchy December 31, 2023 Level 1 Level 2 Level 3 Liabilities Contingent liabilities $ - $ - $ 5,406,000 Total $ - $ - $ 5,406,000
SCHEDULE OF LIABILITIES FAIR VALUE MEASURED	The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs: SCHEDULE OF LIABILITIES FAIR VALUE MEASURED Contingent Liabilities Balance at December 31, 2023 $ 5,406,000 Change in fair value of contingent liabilities 57,000 Balance at September 30, 2024 $ 5,463,000

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITIES	The following table summarizes supplemental condensed consolidated balance sheet information related to the operating leases as of September 30, 2024, and December 31, 2023: SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITIES September 30, 2024 December 31, 2023 Operating lease right-of-use assets $ 797,405 $ 1,101,211 Operating lease liabilities, current $ 442,221 $ 434,082 Operating lease liabilities, non-current 355,184 667,129 Total operating lease liabilities $ 797,405 $ 1,101,211
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	As of September 30, 2024, the maturities of the lease liabilities for the periods ending December 31 are as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2024 $ 108,521 2025 444,934 2026 266,034 Total lease payments 819,489 Less: Present value discount (22,084 ) Total $ 797,405

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSE	SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSE   September 30, 2024   Gross Carrying Amount Accumulated Amortization Net Carrying Amount Patents in process $ 122,745 $ - $ 122,745 DuraGraft patent 5,256,000 (1,684,614 ) 3,571,386 DuraGraft - Distributor relationship 308,000 (128,333 ) 179,667 DuraGraft IPR&D - Cyto Protectant Life Sciences 10,164,000 - 10,164,000 Total intangible assets, net $ 15,850,745 $ (1,812,947 ) $ 14,037,798 December 31, 2023 Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Krillase intangible assets $ 4,250,000 $ - $ (4,250,000 ) $ - Patents in process 122,745 - - 122,745 DuraGraft patent 5,256,000 (1,381,383 ) - 3,874,617 DuraGraft - Distributor relationship 308,000 (105,233 ) - 202,767 DuraGraft IPR&D - Cyto Protectant Life Sciences 12,606,000 - (2,442,000 ) 10,164,000 My Health Logic - Trade name 450,000 (65,090 ) (384,910 ) - My Health Logic - Biotechnology 4,600,000 (547,941 ) (4,052,059 ) - My Health Logic - Software 1,550,000 (209,249 ) (1,340,751 ) - Total intangible assets, net $ 29,142,745 $ (2,308,896 ) $ (12,469,720 ) $ 14,364,129
SCHEDULE OF GOODWILL	SCHEDULE OF GOODWILL Goodwill DuraGraft My Health Logic Total Balance, December 31, 2023 and September 30, 2024 $ 5,416,000 $ - $ 5,416,000
SCHEDULE OF INTANGIBLE ASSETS	The following changes to the Company’s intangible assets had taken place in the periods indicated: SCHEDULE OF INTANGIBLE ASSETS Balance, December 31, 2022 $ 27,675,020 Impairment (12,469,720 ) Amortization expense (841,171 ) Balance, December 31, 2023 14,364,129 Amortization expense (326,331 ) Balance, September 30, 2024 $ 14,037,798

CONVERTIBLE PROMISSORY NOTES _2

CONVERTIBLE PROMISSORY NOTES AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2024
Short-Term Debt [Line Items]
SCHEDULE OF CONVERTIBLE NOTES	The following table summarizes supplemental balance sheet information related to the convertible notes, net of debt discount outstanding, as of September 30, 2024 and December 31, 2023: SCHEDULE OF CONVERTIBLE NOTES Balance, December 31, 2022 $ 2,751,633 Issuance costs - Debt accretion - Settlement of debt - Issuance of convertible notes - Debt accretion on Original securities 1,835,741 Debt extinguishment (4,587,374 ) Convertible notes issued - new securities 19,403,385 Debt discount (344,959 ) Debt interest and accretion on new securities 1,429,646 Mandatory default amount 6,835,105 Conversion of debt (9,509,505 ) Extinguishment of debt (10,276,925 ) Convertible notes issued with extended maturity date 8,791,729 Balance, December 31, 2023 16,328,476 Debt interest and accretion 1,260,775 Extinguishment of debt (6,160,552 ) Convertible notes issued with extended maturity date 5,270,001 Balance, September 30, 2024 $ 16,698,700
SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT	SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT September 30, 2024 December 31, 2023 Convertible notes - total principal $ 17,272,077 $ 17,516,865 Unamortized issuance costs and discount (573,377 ) (1,188,389 ) Convertible Notes, Net of Debt Discount $ 16,698,700 $ 16,328,476 September 30, 2024 December 31, 2023 Current portion $ 16,698,700 $ 16,328,476 Non-current portion - - Convertible Notes, Net of Debt Discount $ 16,698,700 $ 16,328,476
OID Convertible Notes [Member]
Short-Term Debt [Line Items]
SCHEDULE OF CONVERTIBLE NOTES	The following table summarizes supplemental balance sheet information related to the OID Convertible Notes, net of debt discount outstanding, as of September 30, 2024 and December 31, 2023: SCHEDULE OF CONVERTIBLE NOTES OID Convertible Notes, Net of Debt Discount Balance, December 31, 2022 $ - Issuance of convertible notes 6,987,606 Issuance cost (1,583,154 ) Debt discount (5,404,452 ) Debt accretion 2,694,256 Balance, December 31, 2023 2,694,256 Debt accretion 4,885,930 Extinguishment of debt (7,264,572 ) Settlement of debt (109,437 ) Convertible note issued with extended maturity date 6,215,741 Balance, September 30, 2024 $ 6,421,918
SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT	SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT September 30, 2024 December 31, 2023 Convertible notes - total principal $ 6,841,769 $ 6,987,606 Unamortized issuance costs and discount (419,851 ) (4,293,350 ) Convertible Notes, Net of Debt Discount $ 6,421,918 $ 2,694,256 September 30, 2024 December 31, 2023 Current portion $ 6,421,918 $ 2,694,256 Non-current portion - - Convertible Notes, Net of Debt Discount $ 6,421,918 $ 2,694,256

STOCKHOLDERS_ EQUITY (DEFICIT)

STOCKHOLDERS’ EQUITY (DEFICIT) (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	The summary of option activity for the six months ended September 30, 2024, is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of Options Weighted Average Exercise Price Weighted Average Contractual Life Total Intrinsic Value Outstanding at December 31, 2022 3,925,943 $ 1.33 6.06 $ - Granted/forfeited - - - - Outstanding at December 31, 2023 3,925,943 1.33 5.06 - Forfeited (211,667 ) 1.64 - - Expired (1,168,333 ) 1.08 - Outstanding at September 30, 2024 2,545,943 1.42 6.07 - Exercisable at September 30, 2024 2,485,943 $ 1.41 6.04 $ -
SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE	As of September 30, 2024, the Company had the following options outstanding: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Exercise Price Number of Options Outstanding Number of Options Exercisable Weighted Average Remaining Contractual Years Intrinsic Value $ 1.01 890,943 890,943 4.55 $ - 1.25 415,000 415,000 6.40 - 1.37 200,000 200,000 5.88 - 1.75 800,000 770,000 7.16 - 2.20 240,000 210,000 7.69 - $ 1.44 2,545,943 2,485,943 6.07 $ -
SCHEDULE OF WARRANTS OUTSTANDING	SCHEDULE OF WARRANTS OUTSTANDING Number Weighted Average Price Balance, December 31, 2022 20,048,497 $ 2.64 Warrants modified pursuant to debt extinguishment (Note 7) 355,577,447 0.1 Issued pursuant to debt agreements (Note 7) 183,560,497 0.15 Issued 79,949,352 0.11 Exercised (2,652,159 ) 0.1 Balance, December 31, 2023 636,483,634 $ 0.12 Cancelled (2,941,200 ) 0.15 Balance, September 30, 2024 633,542,434 $ 0.12

RESTATEMENT OF PREVIOUSLY ISS_2

RESTATEMENT OF PREVIOUSLY ISSUED UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Changes and Error Corrections [Abstract]
SCHEDULE OF RESTATEMENT FINANCIAL STATEMENTS	The restatement had no impact on total net cash flows from operating, investing, or financing activities. SCHEDULE OF RESTATEMENT FINANCIAL STATEMENTS Consolidated Balance Sheet – as March 31, 2024 Originally Reported Restatement Adjustment As As of March 31, 2024 (Unaudited) Originally Reported Restatement Adjustment As LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT Current portion of Convertible Notes - Units Private Placement $ 15,807,061 $ 409,974 $ 16,217,035 Current portion of Convertible Notes - OID $ 5,448,468 $ (607,569 ) $ 4,840,899 Total current liabilities $ 25,847,800 $ (197,595 ) $ 25,650,205 Total liabilities $ 32,402,707 $ (197,595 ) $ 32,205,112 Stockholders’ deficit: Additional paid-in capital $ 146,598,185 $ 3,560,213 $ 150,158,398 Accumulated deficit $ (157,562,641 ) $ (3,362,618 ) $ (160,925,259 ) Consolidated Statement of Operations and Comprehensive Loss - Three Months Ended March 31, 2024 Originally Reported Restatement Adjustment As Three months ended March 31, 2024 (Unaudited) Originally Reported Restatement Adjustment As Interest and accretion expenses $ (4,161,830 ) $ 1,427,891 $ (2,733,939 ) Loss on debt extinguishment $ (107,370 ) $ (598,089 ) $ (705,459 ) Total other income (expense) $ (4,854,200 ) $ 829,802 $ (4,024,398 ) Net loss $ (6,226,292 ) $ 829,802 $ (5,396,490 ) Loss per share – basic and diluted $ (0.05 ) $ 0.01 $ (0.04 ) Consolidated Statement of Stockholders’ Deficit – Three Months Ended March 31, 2024 Originally Reported Restatement Adjustment As Three month ended March 31, 2024 (Unaudited) Originally Reported Restatement Adjustment As Increase of fair value of warrants in debt extinguishment $ - $ (1,407,934 ) $ (1,407,934 ) Net loss $ (6,226,292 ) $ 829,802 $ (5,396,490 ) Total stockholders’ deficit $ (10,832,664 ) $ 197,595 $ (10,635,069 ) Consolidated Statement of Cash Flows – Three Months Ended March 31, 2024 Originally Reported Restatement Adjustment As Three months ended March 31, 2024 (Unaudited) Originally Reported Restatement Adjustment As Net loss $ (6,226,292 ) $ 829,802 $ (5,396,490 ) Interest and accretion on convertible notes and notes payable $ 4,161,830 $ (1,427,891 ) $ 2,733,939 Loss on debt extinguishment $ 107,370 $ 598,089 $ 705,459 Consolidated Balance Sheet – as June 30, 2024 Originally Reported Restatement Adjustment As As of June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT Current portion of Convertible Notes - Units Private Placement $ 17,022,717 $ (482,186 ) $ 16,540,531 Current portion of Convertible Notes - OID $ 990,636 $ 5,055,776 $ 6,046,412 Total current liabilities $ 23,551,638 $ 4,573,590 $ 28,125,228 Total liabilities $ 30,914,541 $ 4,573,590 $ 35,488,131 Stockholders’ deficit: Additional paid-in capital $ 152,123,457 $ 2,152,278 $ 154,275,735 Accumulated deficit $ (161,635,217 ) $ (6,725,868 ) $ (168,361,085 ) Consolidated Statement of Operations and Comprehensive Loss - Three Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Three months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Interest and accretion expenses $ (2,938,416 ) $ 546,735 $ (2,391,681 ) Gain (loss) on debt extinguishment $ 667,200 $ (3,909,985 ) $ (3,242,785 ) Total other income (expense) $ (2,483,216 ) $ (3,363,250 ) $ (5,846,466 ) Net loss $ (4,072,576 ) $ (3,363,250 ) $ (7,435,826 ) Loss per share – basic and diluted $ (0.03 ) $ ( 0.03 ) $ (0.06 ) Consolidated Statement of Stockholders’ Deficit – Three Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Three months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Increase of fair value of warrants in debt extinguishment $ - $ 4,075,749 $ 4,075,749 Modification of warrants $ 5,483,684 $ (5,483,684 ) - Net loss $ (4,072,576 ) $ (3,363,250 ) $ (7,435,826 ) Total stockholders’ deficit $ (9,379,968 ) $ (4,573,590 ) $ (13,953,558 ) Consolidated Statement of Operations and Comprehensive Loss - Six Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Six months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Interest and accretion expenses $ (7,100,246 ) $ 1,974,626 $ (5,125,620 ) Gain on debt extinguishment $ 559,830 $ (4,508,074 ) $ (3,948,244 ) Total other income (expense) $ (7,337,416 ) $ (2,533,448 ) $ (9,870,864 ) Net loss $ (10,298,868 ) $ (2,533,448 ) $ (12,832,316 ) Loss per share – basic and diluted $ (0.08 ) $ ( 0.02 ) $ (0.10 ) Consolidated Statement of Stockholders’ Deficit – Six Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Six months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Increase of fair value of warrants in debt extinguishment $ - $ 5,483,683 $ 5,483,683 Modification of warrants $ 5,483,684 $ (5,483,684 ) - Net loss $ (10,298,868 ) $ (2,533,448 ) $ (12,832,316 ) Total stockholders’ deficit $ (9,379,968 ) $ (4,573,590 ) $ (13,953,558 ) Consolidated Statement of Cash Flows – Six Months Ended June 30, 2024 Originally Reported Restatement Adjustment As Six months ended June 30, 2024 (Unaudited) Originally Reported Restatement Adjustment As Net loss $ (10,298,868 ) $ (2,533,448 ) $ (12,832,316 ) Interest and accretion on convertible notes and notes payable $ 7,100,246 $ (1,974,626 ) $ 5,125,620 Gain (loss) on debt extinguishment $ (559,830 ) $ 4,508,074 $ 3,948,244

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	1 Months Ended
	Jul. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accumulated deficit		$ (170,320,946)	$ (168,361,085)	$ (160,925,259)	$ (155,528,769)
Working capital		(29,122,609)			(21,673,945)
Cash		63,732			$ 148,465
Short-term loans		$ 1,027,400
Co-Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment capital	$ 1,250,000

SCHEDULE OF FAIR VALUES OF FINA

SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Platform Operator, Crypto Asset [Line Items]
Contingent liabilities	$ 5,463,000	$ 5,406,000
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto Asset [Line Items]
Contingent liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto Asset [Line Items]
Contingent liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto Asset [Line Items]
Contingent liabilities	5,463,000	5,406,000
Total	$ 5,463,000	$ 5,406,000

SCHEDULE OF LIABILITIES FAIR VA

SCHEDULE OF LIABILITIES FAIR VALUE MEASURED (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Platform Operator, Crypto Asset [Line Items]
Change in fair value of contingent liabilities	$ 440,000	$ (1,678,000)	$ (57,000)	$ 312,000
Fair Value, Inputs, Level 3 [Member] | Derivative and Contingent Liabilities [Member]
Platform Operator, Crypto Asset [Line Items]
Beginning Balance			5,406,000
Change in fair value of contingent liabilities			57,000
Ending Balance	$ 5,463,000		$ 5,463,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Midrange average estimated interest rate					20.60%
Liabilities fair value adjustment	$ 409,000		$ 1,262,000		$ 228,000	$ 466,000
Royalty payments					3,586,000		$ 3,358,000
Adjustment of warrants					$ 5,827,782
Goodwill [Member]
Intangible asset percentage	33.80%				33.80%
In Process Research And Development Assets [Member]
Discount rate intangible asset percentage	35.20%				35.20%
Scenario, Adjustment [Member]
Pre tax discount rate percentage					20.60%
Market value
Warrants Liabilities [Member]
Risk free rate					1.19%
Expected volatility					69.62%
Expected dividend
Expected life					5 years 11 months 15 days
Increase (decrease) in operating liabilities	$ 31,000		$ 406,000		$ 171,000	$ 800,000
Warrants liabilities					$ 54,000		225,000
Liquidation Preference [Member]
Risk free rate					0.21%
Expected volatility					78.93%
Expected dividend
Expected life					5 years
Liquidation preference fair market value	1,823,000				$ 1,823,000		$ 1,823,000
OID Convertible Notes [Member]
Risk free rate					4.25%
Expected volatility					349.95%
Expected dividend
Expected life					2 months 1 day
Adjustment of warrants					$ 5,827,782
Convertible notes	$ 4,778,950				$ 4,778,950

SCHEDULE OF RIGHT-OF-USE ASSET

SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITIES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Leases
Operating lease right-of-use assets	$ 797,405	$ 1,101,211
Operating lease liabilities, current	442,221	434,082
Operating lease liabilities, non-current	355,184	667,129
Total operating lease liabilities	$ 797,405	$ 1,101,211

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Leases
2024	$ 108,521
2025	444,934
2026	266,034
Total lease payments	819,489
Less: Present value discount	(22,084)
Total	$ 797,405	$ 1,101,211

LEASES (Details Narrative)

LEASES (Details Narrative)				1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 01, 2022 USD ($) ft²	Mar. 31, 2022 USD ($)	Dec. 11, 2020 ft²	Dec. 31, 2020 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease agreement, description			five-and-a-half-year lease agreement
Administrative office and laboratories space | ft²			10,300
Payments for rent					$ 129,416	$ 81,502	$ 290,474	$ 274,004
Operating expenses					$ 1,355,030	$ 4,987,756	$ 4,339,690	$ 12,149,448
Operating Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Administrative office and laboratories space | ft²	3,053
Payments for rent	$ 15,641			$ 10,800
Annually percentage				2.50%			2.50%
Operating expenses				$ 12,000
Increase in operating lease							$ 16,032
Operating lease expense	$ 17,500	$ 12,000
Lease term					1 year 9 months 29 days		1 year 9 months 29 days
Operating lease discount rate					3.95%		3.95%

SCHEDULE OF INTANGIBLE ASSETS A

SCHEDULE OF INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Sep. 30, 2024	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 29,142,745	$ 15,850,745
Accumulated amortization	(2,308,896)	(1,812,947)
Net carrying amount	14,364,129	14,037,798	$ 27,675,020
Impairment	(12,469,720)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	122,745	122,745
Accumulated amortization
Net carrying amount	122,745	122,745
Impairment
DuraGraft Patent [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	5,256,000	5,256,000
Accumulated amortization	(1,381,383)	(1,684,614)
Net carrying amount	3,874,617	3,571,386
Impairment
DuraGraft Distributor Relationship [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	308,000	308,000
Accumulated amortization	(105,233)	(128,333)
Net carrying amount	202,767	179,667
Impairment
DuraGraft Cyto Protectant [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	12,606,000	10,164,000
Accumulated amortization
Net carrying amount	10,164,000	$ 10,164,000
Impairment	(2,442,000)
Krillase Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	4,250,000
Accumulated amortization
Net carrying amount
Impairment	(4,250,000)
My Health Logic - Trade Name [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	450,000
Accumulated amortization	(65,090)
Net carrying amount
Impairment	(384,910)
My Health Logic - Biotechnology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	4,600,000
Accumulated amortization	(547,941)
Net carrying amount
Impairment	(4,052,059)
My Health Logic - Software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	1,550,000
Accumulated amortization	(209,249)
Net carrying amount
Impairment	$ (1,340,751)

SCHEDULE OF GOODWILL (Details)

SCHEDULE OF GOODWILL (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Impairment Effects on Earnings Per Share [Line Items]
Balance	$ 5,416,000	$ 5,416,000
DuraGraft [Member]
Impairment Effects on Earnings Per Share [Line Items]
Balance	5,416,000	5,416,000
My Health Logic [Member]
Impairment Effects on Earnings Per Share [Line Items]
Balance

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance	$ 14,364,129	$ 27,675,020
Impairment		(12,469,720)
Amortization expense	(326,331)	(841,171)
Ending Balance	$ 14,037,798	$ 14,364,129

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 12, 2018
Finite-Lived Intangible Assets [Line Items]
Net carrying amount	$ 14,037,798	$ 14,364,129	$ 27,675,020
Impairment of intangible assets		12,469,720
Impairment of intangible assets		(12,469,720)
Goodwill	5,416,000	5,416,000
DuraGraft and My Health Logic [Member]
Finite-Lived Intangible Assets [Line Items]
2025	435,108
2026	435,108
2027	435,108
2028	435,108
2029	435,108
2030 and thereafter	1,575,512
Krillase Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Business acquition intangibles assets						$ 28,600,000
Net carrying amount
Impairment of intangible assets	0	4,250,000
DuraGraft [Member]
Finite-Lived Intangible Assets [Line Items]
Business acquition intangibles assets					$ 18,170,000
Impairment of intangible assets		2,442,000
Intangible assets impairment	$ 0	14,241,384
My Health Logic, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Business acquition intangibles assets				$ 6,600,000
Impairment of intangible assets		5,777,720
Goodwill				$ 1,774,656
Impairment charges, goodwill		$ 1,774,656

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)					3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 23, 2023	May 30, 2023	Feb. 02, 2023	Dec. 28, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2022	Jul. 12, 2024	Dec. 31, 2023	Feb. 01, 2023	Nov. 30, 2021
Mr Richamond [Member]
Notes payable					$ 441,000		$ 441,000				$ 151,000
Dr. Vithalbhai Dhaduk [Member]
Notes payable					52,000		52,000
Hexin Promissory Note [Member]
Notes payable				$ 750,000
Interest rate				20%
Interest expenses											64,133
Debt outstanding				$ 814,133	47,446		47,446
Conversion units				9,578,040
Hub International Limited [Member]
Notes payable	$ 165,469										130,122
Interest rate	8%
Debt instrument, maturity date	Aug. 23, 2024
Walleye Opportunities Master Fund Ltd. [Member]
Notes payable			$ 1,000,000
Debt instrument, maturity date			May 07, 2023
Interest expenses											250,000
Debt outstanding			$ 1,250,000
Conversion units		14,705,890
Notes payable increased			1,250,000
Principal amount			$ 1,250,000									$ 1,000,000
MyHealth Logic Acquisition [Member]
Notes payable													$ 468,137
Interest rate													9%
Debt outstanding					264,535		264,535				252,223
Aggregate amount settled									$ 278,678
Debt accrued interest					5,868	$ 5,344	17,010	$ 23,710
Santander Bank Sullivan and Worcester LLP [Member]
Notes payable					515,000		515,000				65,000
Commas International Holding, LLC [Member]
Notes payable					$ 170,000		$ 170,000
Qualigen Therapeutics Inc [Member]
Interest rate										18%
Principal amount										$ 1,250,000

SCHEDULE OF CONVERTIBLE NOTES (

SCHEDULE OF CONVERTIBLE NOTES (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Beginning balance	$ 16,328,476	$ 2,751,633
Issuance costs
Debt accretion
Settlement of debt
Issuance of convertible notes
Debt accretion on Original securities		1,835,741
Debt extinguishment		(4,587,374)
Convertible notes issued - new securities		19,403,385
Debt discount		(344,959)
Debt accretion new sercurities		1,429,646
Mandatory Default Amount		6,835,105
Conversion of debt		(9,509,505)
Extinguishment of debt	(6,160,552)	(10,276,925)
Convertible note issued with extended maturity date		8,791,729
Debt interest and accretion	1,260,775
Convertible notes issued with extended maturity date	5,270,001
Ending balance	16,698,700	16,328,476
OID Convertible Notes [Member]
Short-Term Debt [Line Items]
Beginning balance	2,694,256
Issuance costs		(1,583,154)
Debt accretion	4,885,930	2,694,256
Settlement of debt	109,437
Issuance of convertible notes		6,987,606
Debt discount		5,404,452
Extinguishment of debt	(7,264,572)
Convertible note issued with extended maturity date	6,215,741
Ending balance	$ 6,421,918	$ 2,694,256

SCHEDULE OF CONVERTIBLE NOTES N

SCHEDULE OF CONVERTIBLE NOTES NET OF DEBT DISCOUNT (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible notes - total principal	$ 17,272,077	$ 17,516,865
Unamortized issuance costs and discount	(573,377)	(1,188,389)
Convertible Notes, Net of Debt Discount	16,698,700	16,328,476	$ 2,751,633
Current portion	16,698,700	16,328,476
Non-current portion
OID Convertible Notes [Member]
Short-Term Debt [Line Items]
Convertible notes - total principal	6,841,769	6,987,606
Unamortized issuance costs and discount	(419,851)	(4,293,350)
Convertible Notes, Net of Debt Discount	6,421,918	2,694,256
Current portion	6,421,918	2,694,256
Non-current portion

CONVERTIBLE PROMISSORY NOTES _3

CONVERTIBLE PROMISSORY NOTES AND WARRANTS (Details Narrative) - USD ($)		3 Months Ended				6 Months Ended	9 Months Ended		12 Months Ended
	Dec. 11, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Shares issued in aggregate									4,207,828	4,180,071	4,260,594
Proceeds from Issuance of Common Stock									$ 344,959	$ 6,500,743	$ 6,692,765
Fair value of warrants								$ 12,666,268	12,666,268
Loss on extinguishment of debt									21,777,877
Convertible debt									$ 9,340,774
Gain loss on debt extinguishment		$ 59,843	$ (3,242,785)	$ (705,459)	$ (80,000)	$ (3,948,244)	(3,888,401)	(21,857,877)
Interest and accretion expenses		433,868			529,596		1,260,775	3,265,387
Loss on issuance of debt					3,974,993			6,352,562
Fair value of warrants							5,827,782
Loss on debt extinguishment
Interest and acceration expenses		613,186			$ 843,699		4,885,930	993,785
Class E Warrant [Member]
Short-Term Debt [Line Items]
Conertible warrants									$ 0.10
Class F Warrant [Member]
Short-Term Debt [Line Items]
Conertible warrants									0.20
OID Convertible Notes [Member]
Short-Term Debt [Line Items]
Debt discount							4,778,950
Fair value of warrants							5,827,782
Convertible notes		4,778,950					4,778,950
Private Placement [Member]
Short-Term Debt [Line Items]
Conertible warrants									$ 0.10
Warrants outstanding									$ 10,000,000
Warrants units									100,000,000
Percentage of original issue discount									15%
Warrant purchase percentage									125%
Convertible Notes [Member]
Short-Term Debt [Line Items]
Principal amount									$ 1,000,000
Maturity date									May 07, 2023
Mandatory default description									the Company also defaulted under the Convertible Notes on the same date. As the result, the Company accreted a default amount of $6,791,185 to the value of the Convertible Notes in 2023.
Gain loss on debt extinguishment							890,549	$ (21,777,877)
Loss on issuance of debt									$ 6,888,475
OID Convertible Notes [Member]
Short-Term Debt [Line Items]
Principal amount		6,841,769					6,841,769		$ 6,987,606
Conversion into shares									69,876,060
Debt discount									$ 5,404,452
Convertible notes		$ 6,421,918					$ 6,421,918		$ 2,694,256
Convertible Debt [Member]
Short-Term Debt [Line Items]
Shares outstanding									8,269,237
Shares replacement units									190,584,260
2023 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument conversion description							The OID Convertible Notes mature nine months from the date of the OID Units Initial Closing and accrue 10% of interest per annum on the outstanding principal amount. The OID Convertible Notes are unsecured and subordinated to any senior indebtedness of the Company. The OID Convertible Notes’ principal and accrued interest may generally be converted at any time at a conversion price of $0.10 per share, subject to adjustment, at the option of the holder, into shares of common stock, subject to certain limitations: (i) conversion would not cause the holder to beneficially own more than 4.99% of the Company’s common stock, or more than 9.99% if the holder beneficially owns more than 4.99% of common stock based on ownership of equity securities of the Company other than the OID Convertible Notes or the respective warrants; and (ii) the Company’s articles of incorporation have been amended to increase the number of authorized shares of common stock to a sufficient amount to permit the full conversion of the OID Convertible Notes (the “Capital Event Amendment”).
2023 Warrants Terms [Member]
Short-Term Debt [Line Items]
Class of warrant description							The Class E Warrants and Class F Warrants are generally exercisable for a period from the date of the Capital Event Amendment until five years from the date of issue. The exercise right is subject to a similar beneficial ownership limitation that applies to conversion of the OID Convertible Notes above, i.e., exercise is permitted only if it would not cause the holder to beneficially own more than 4.99% of the Company’s common stock, or more than 9.99% if the holder beneficially owns more than 4.99% of common stock based on ownership of equity securities of the Company other than the OID Convertible Notes or the Class E Warrants and Class F Warrants.
Class C Warrant [Member]
Short-Term Debt [Line Items]
Conertible warrants									$ 0.10
Warrant [Member]
Short-Term Debt [Line Items]
Warrants units		633,542,434					633,542,434		636,483,634
Decrease in fair value of this liability	$ 795,934
Fair value of warrants	$ 11,496,701
Warrant [Member] | Convertible Notes [Member]
Short-Term Debt [Line Items]
Decrease in fair value of this liability									$ 12,292,635

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Number of Options, Outstanding Beginning Balance	3,925,943	3,925,943
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 1.33	$ 1.33
Weighted average contractual life term, outstanding	6 years 25 days	5 years 21 days	6 years 21 days
Total Intrinsic Value, Beginning balance
Number of Options, Forfeited	(211,667)
Weighted Average Exercise Price, Forfeited	$ 1.64
Number of Options, Expired	(1,168,333)
Weighted Average Exercise Price, Expired	$ 1.08
Number of Options, Outstanding Ending Balance	2,545,943	3,925,943	3,925,943
Weighted Average Exercise Price, Outstanding Ending Balance	$ 1.42	$ 1.33	$ 1.33
Total Intrinsic Value, Ending balance
Number of options, Exercisable	2,485,943
Weighted Average Exercise Price, Exercisable	$ 1.41
Weighted average contractual life term, exercisable	6 years 14 days
Total Intrinsic Value, exercisable

SCHEDULE OF OPTIONS OUTSTANDING

SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Intrinsic Value
Exercise Price Range 1.01 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.01
Number of Options Outstanding	890,943
Number of Options Exercisable	890,943
Weighted Average Remaining Contractual Years	4 years 6 months 18 days
Intrinsic Value
Exercise Price Range 1.25 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.25
Number of Options Outstanding	415,000
Number of Options Exercisable	415,000
Weighted Average Remaining Contractual Years	6 years 4 months 24 days
Intrinsic Value
Exercise Price Range 1.37 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.37
Number of Options Outstanding	200,000
Number of Options Exercisable	200,000
Weighted Average Remaining Contractual Years	5 years 10 months 17 days
Intrinsic Value
Exercise Price Range 1.75 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.75
Number of Options Outstanding	800,000
Number of Options Exercisable	770,000
Weighted Average Remaining Contractual Years	7 years 1 month 28 days
Intrinsic Value
Exercise Price Range 2.20 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 2.20
Number of Options Outstanding	240,000
Number of Options Exercisable	210,000
Weighted Average Remaining Contractual Years	7 years 8 months 8 days
Intrinsic Value
Exercise Price Range 1.44 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.44
Number of Options Outstanding	2,545,943
Number of Options Exercisable	2,485,943
Weighted Average Remaining Contractual Years	6 years 25 days
Intrinsic Value

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING (Details) - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Beginning balance	636,483,634	20,048,497
Weighted Average Price, Warrants outstanding, beginning balance	$ 0.12	$ 2.64
Warrants, Warrants modified pursuant to debt extinguishment		$ 355,577,447
Weighted average exercise price, Warrants modified pursuant to debt extinguishment		$ 0.1
Warrants, issued		79,949,352
Weighted average exercise price, Issued		$ 0.11
Warrants, Exercised		(2,652,159)
Weighted average exercise price, Exercised		$ 0.1
Warrants, Cancelled	(2,941,200)
Weighted average exercise price, Cancelled	$ 0.15
Warrants, Ending balance	633,542,434	636,483,634
Weighted Average Price, Warrants outstanding, Ending balance	$ 0.12	$ 0.12
Debt Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, issued		183,560,497
Weighted average exercise price, Issued pursuant to debt agreements		$ 0.15

STOCKHOLDERS_ EQUITY (DEFICIT_2

STOCKHOLDERS’ EQUITY (DEFICIT) (Details Narrative) - USD ($)		3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Dec. 11, 2023	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2021	Dec. 27, 2022	Dec. 26, 2022	May 18, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized		25,000,000				25,000,000		25,000,000
Preferred stock, par value		$ 0.001				$ 0.001		$ 0.001
Preferred stock, shares issued		0				0		0
Preferred stock, shares outstanding		0				0		0
Common stock, shares authorized		2,000,000,000				2,000,000,000		2,000,000,000
Common stock, par value		$ 0.001				$ 0.001		$ 0.001
Common stock, shares issued		131,793,088				131,793,088		131,793,088
Common stock, shares outstanding		131,793,088				131,793,088		131,793,088
Share-based payment award, options, grants in period, gross
Compensation cost		$ 0				$ 0
Gross proceeds from sale of equity						5,000,000
Fair value of warrants						5,827,782
Non-cash share-based compensation		$ 20,794		$ 86,123		116,646	$ 457,860
OID Convertible Notes [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value of warrants						5,827,782
Convertible notes						$ 4,778,950
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants		633,542,434				633,542,434		636,483,634
Fair value of warrants	$ 11,496,701
Directors, Senior Officers and Consultants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted share awards granted									350,000
Stock Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share authorized												5,300,000
Number of shares available for issuance		4,304,724				4,304,724		2,924,057		7,200,000	1,900,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Professional fees related paty	$ 118,270	$ 921,552	$ 721,042	$ 1,818,202
Related Party [Member]
Related Party Transaction [Line Items]
Related party transactions owned	302,900		302,900		$ 230,153
Professional fees related paty	277,000	404,750	882,000	1,214,250
Outstanding balance for services	302,900		302,900		7,653
Director and Executive Officers [Member]
Related Party Transaction [Line Items]
Professional fees related paty	208,500	257,750	632,500	773,250
Outstanding balance for services	292,500		292,500		222,500
DuraGraft [Member]
Related Party Transaction [Line Items]
Royalties payable		$ 13,014	1,957	$ 211,262
Somahlution [Member]
Related Party Transaction [Line Items]
Decrease in prepaid royalties					151,000
Prepaid royalties	$ 120,500		$ 120,500		$ 122,457

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
DuraGraft [Member]
Loss Contingencies [Line Items]
Prepaid royalties		$ 1,957
Sale of asset percentage		15%
DuraGraft [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Net proceeds from sale of asset		$ 20,000,000
UNITED STATES | First 50,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage		5%
UNITED STATES | 50,000,001 up to 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage		4%
UNITED STATES | Over 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage		2%
Non-US [Member] | First 50,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage		6%
Non-US [Member] | 50,000,001 up to 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage		4%
Non-US [Member] | Over 200,000,000 [Member]
Loss Contingencies [Line Items]
Royalties percentage		2%

AGREEMENT OBLIGATION (Details N

AGREEMENT OBLIGATION (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Apr. 30, 2024	Sep. 30, 2024
Agreement Obligation [Member]
Investment return difference in the amount		$ 500,000
Investment return		$ 1,000,000
Agreement [Member] | Qualigen Therapeutics Inc [Member]
Payments for fees	$ 200,000
Fund received	$ 500,000
Agreement [Member] | Qualigen Therapeutics Inc [Member] | Minimum [Member]
Sales percentage	33%
Contractual obligation	$ 500,000

SCHEDULE OF RESTATEMENT CONSOLI

SCHEDULE OF RESTATEMENT CONSOLIDATED BALANCE SHEET (Details) - USD ($)	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Current portion of Convertible Notes - Units Private Placement	$ 16,698,700	$ 16,540,531	$ 16,217,035	$ 16,328,476
Current portion of Convertible Notes - OID	6,421,918	6,046,412	4,840,899	2,694,256
Total current liabilities	29,977,203	28,125,228	25,650,205	22,642,723
Total liabilities	36,795,387	35,488,131	32,205,112	28,715,852
Additional paid-in capital	154,650,064	154,275,735	150,158,398	148,696,200
Accumulated deficit	$ (170,320,946)	(168,361,085)	(160,925,259)	$ (155,528,769)
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Current portion of Convertible Notes - Units Private Placement		17,022,717	15,807,061
Current portion of Convertible Notes - OID		990,636	5,448,468
Total current liabilities		23,551,638	25,847,800
Total liabilities		30,914,541	32,402,707
Additional paid-in capital		152,123,457	146,598,185
Accumulated deficit		(161,635,217)	(157,562,641)
Revision of Prior Period, Reclassification, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Current portion of Convertible Notes - Units Private Placement		(482,186)	409,974
Current portion of Convertible Notes - OID		5,055,776	(607,569)
Total current liabilities		4,573,590	(197,595)
Total liabilities		4,573,590	(197,595)
Additional paid-in capital		2,152,278	3,560,213
Accumulated deficit		$ (6,725,868)	$ (3,362,618)

SCHEDULE OF RESTATEMENT CONSO_2

SCHEDULE OF RESTATEMENT CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS (Details) - USD ($)	3 Months Ended						6 Months Ended	9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest and accretion expenses	$ (1,104,674)	$ (2,391,681)	$ (2,733,939)	$ (1,502,088)			$ (5,125,620)	$ (6,230,294)	$ (11,038,400)
Gain on debt extinguishment	59,843	(3,242,785)	(705,459)	(80,000)			(3,948,244)	(3,888,401)	(21,857,877)
Total other income (expense)	(604,831)	(5,846,466)	(4,024,398)	(21,689,478)			(9,870,864)	(10,475,695)	(53,391,236)
Net loss	$ (1,959,861)	$ (7,435,826)	$ (5,396,490)	$ (26,546,688)	$ (36,084,039)	$ (2,554,584)	$ (12,832,316)	$ (14,792,177)	$ (65,185,311)
Loss per share - basic	$ (0.01)	$ (0.06)	$ (0.04)	$ (0.58)			$ (0.10)	$ (0.11)	$ (1.51)
Loss per share - diluted	$ (0.01)	$ (0.06)	$ (0.04)	$ (0.58)			$ (0.10)	$ (0.11)	$ (1.51)
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest and accretion expenses		$ (2,938,416)	$ (4,161,830)				$ (7,100,246)
Gain on debt extinguishment		667,200	(107,370)				559,830
Total other income (expense)		(2,483,216)	(4,854,200)				(7,337,416)
Net loss		$ (4,072,576)	$ (6,226,292)				$ (10,298,868)
Loss per share - basic		$ (0.03)	$ (0.05)				$ (0.08)
Loss per share - diluted		$ (0.03)	$ (0.05)				$ (0.08)
Revision of Prior Period, Reclassification, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Interest and accretion expenses		$ 546,735	$ 1,427,891				$ 1,974,626
Gain on debt extinguishment		(3,909,985)	(598,089)				(4,508,074)
Total other income (expense)		(3,363,250)	829,802				(2,533,448)
Net loss		$ (3,363,250)	$ 829,802				$ (2,533,448)
Loss per share - basic		$ 0.03	$ 0.01				$ 0.02
Loss per share - diluted		$ 0.03	$ 0.01				$ 0.02

SCHEDULE OF RESTATEMENT CONSO_3

SCHEDULE OF RESTATEMENT CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (Details) - USD ($)	3 Months Ended						6 Months Ended	9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase of fair value of warrants in debt extinguishment	$ 344,098	$ 4,075,749	$ 1,407,934		$ 12,666,268		$ 5,483,683
Net loss	(1,959,861)	(7,435,826)	(5,396,490)	$ (26,546,688)	(36,084,039)	$ (2,554,584)	(12,832,316)	$ (14,792,177)	$ (65,185,311)
Balance	$ (15,539,090)	(13,953,558)	(10,635,069)	$ (29,401,577)	$ (6,085,702)	$ 15,231,967	(13,953,558)	(15,539,090)	$ (29,401,577)
Modification of warrants								$ 5,827,782
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase of fair value of warrants in debt extinguishment
Net loss		(4,072,576)	(6,226,292)				(10,298,868)
Balance		(9,379,968)	(10,832,664)				(9,379,968)
Modification of warrants		5,483,684					5,483,684
Revision of Prior Period, Reclassification, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase of fair value of warrants in debt extinguishment		4,075,749	1,407,934				5,483,683
Net loss		(3,363,250)	829,802				(2,533,448)
Balance		(4,573,590)	$ 197,595				(4,573,590)
Modification of warrants		$ (5,483,684)					$ (5,483,684)

SCHEDULE OF RESTATEMENT CONSO_4

SCHEDULE OF RESTATEMENT CONSOLIDATED STATEMENT OF CASH FLOWS (Details) - USD ($)	3 Months Ended						6 Months Ended	9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Sep. 30, 2024	Sep. 30, 2023
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss	$ (1,959,861)	$ (7,435,826)	$ (5,396,490)	$ (26,546,688)	$ (36,084,039)	$ (2,554,584)	$ (12,832,316)	$ (14,792,177)	$ (65,185,311)
Interest and accretion on convertible notes and notes payable			2,733,939				5,125,620	6,230,294	11,038,400
Gain (loss) on debt extinguishment	$ (59,843)	3,242,785	705,459	$ 80,000			3,948,244	$ 3,888,401	$ 21,857,877
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss		(4,072,576)	(6,226,292)				(10,298,868)
Interest and accretion on convertible notes and notes payable			4,161,830				7,100,246
Gain (loss) on debt extinguishment		(667,200)	107,370				(559,830)
Revision of Prior Period, Reclassification, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss		(3,363,250)	829,802				(2,533,448)
Interest and accretion on convertible notes and notes payable			(1,427,891)				(1,974,626)
Gain (loss) on debt extinguishment		$ 3,909,985	$ 598,089				$ 4,508,074

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Dec. 31, 2024	Sep. 30, 2024	Jul. 12, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 28, 2022
Hexin Promissory Note [Member]
Subsequent Event [Line Items]
Notes payable						$ 750,000
Additional funding		$ 47,446				$ 814,133
Annual interest rate						20%
Qualigen Therapeutics Inc [Member]
Subsequent Event [Line Items]
Annual interest rate			18%
Subsequent Event [Member] | Qualigen Therapeutics Inc [Member] | Hexin Promissory Note [Member]
Subsequent Event [Line Items]
Additional funding	$ 707,404
Annual interest rate	18%
Dr. Vithalbhai Dhaduk [Member]
Subsequent Event [Line Items]
Notes payable		$ 52,000
Dr. Vithalbhai Dhaduk [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Notes payable	$ 52,000